Evolysse is new, has two products, one approved use, and a published record that stops at 12 months. FDA approved Evolysse Smooth and Evolysse Form on 13 February 2025. Juvederm's first approval dates from 2 June 2006, and its seven products have accumulated separate approved uses across a dozen areas of the face and neck since.
Evolysse is approved for one thing. The wording covers "dermal and subdermal injection to correct moderate to severe dynamic facial wrinkles and folds (such as NLFs) in adults 22 years or older" — that is the whole indication for both products. Evolysse has no lip, cheek, chin, jawline, temple or under-eye approval.
The trial behind Evolysse compared it with Restylane-L, not with any Juvederm product. It was a split-face, double-blind study in 140 people, and it was a non-inferiority design — built to rule out a difference bigger than half a grade, not to show that anything was better. No trial has ever compared Evolysse with Juvederm.
How much you know about Evolysse depends heavily on which measurement you look at. In the same people at the same visit, independent photo review scored 45 to 52% as responders while live evaluators scored 95 to 98%. That gap is the most instructive thing in the Evolysse file, and it applies to every filler number you will ever read.
The approval holder is Symatese; Evolus is the US commercial partner.
Every later Juvederm product was added as a supplement to one of those two approvals, each with its own review and its own date.
Other names that appear in trade press, such as Evolysse Lips and Evolysse Sculpt, have no FDA record and are not approved products here.
Both Smooth and Form share that single indication. Anything else is off-label — which is legal and common, but it means there is no trial behind it.
Folds, lips, lines around the mouth, cheeks, chin, temples, jawline definition, the under-eye hollow, and skin smoothness of the cheeks and neck. Each belongs to a named product, not to the brand.
Crosslinked with BDDE, the same crosslinker used across the category. Evolus markets the process as Cold-X, a name that does not appear in the FDA record.
Allergan's Hylacross and Vycross names are also absent from the FDA record.
Non-inferiority means the trial was designed to rule out a difference larger than half a grade. It is not a demonstration that either product is better, and it is not a proven tie.
Volbella XC's lip trial was run against Restylane-L. Juvederm Voluma XC has appeared as the named comparator in two other manufacturers' cheek trials, both also non-inferiority designs.
By independent photo review, 64.6% of Smooth and 72.1% of Form subjects met a one-grade improvement at 12 months. At 6 months the same photo review gave 51.6% and 45.2% — lower than at 12 months, which points to measurement noise rather than a filler that improved with time.
Ultra XC ran 24 weeks in folds and 12 months in lips. Vollure XC ran 18 months. Voluma XC ran 24 months. Volux XC ran 12 months. Skinvive ran 6 months.
There is no independent published literature on Evolysse and no accumulated post-market record, because it has only been on the US market since early 2025.
Small MRI series have found hyaluronic acid still detectable years after injection. That is persistence of material, not continued cosmetic effect, and the series are small and selected.
The Evolysse trial reported its results two ways, in the same people, at the same visits. Independent reviewers scoring photographs on a wrinkle severity scale found 45 to 52% responders at 6 months. Blinded live evaluators using a global improvement scale, looking at the same subjects on the same day, found 95 to 98%.
Neither number is dishonest. They measure different things, with different assessors, against different definitions of improvement. But the gap between them is enormous, and it explains why a claim like "97% of patients saw improvement" tells you almost nothing on its own. Ask which scale, and who was doing the scoring.
The same trial also shows why single timepoints mislead. The photo-review responder rate for Evolysse Smooth was lower at 6 months than at 12. A filler does not get better between month 6 and month 12. What changed was the denominator and the noise in the measurement.
The approved wording for both Evolysse products says "dynamic facial wrinkles and folds". Most US filler approvals just say "facial wrinkles and folds". The word is a genuine part of the regulatory text rather than marketing, and it reflects how the application was framed. What it does not do is establish that Evolysse performs better in areas that move — that comparison has not been made against any other product.
Evolysse went through premarket approval, the FDA's strictest device route, which required a controlled clinical trial before it could be sold. In that sense it is not an unknown quantity — it is held to exactly the same standard as Juvederm.
What it lacks is time. Rare and delayed problems with fillers, such as delayed inflammatory nodules appearing months after injection, tend to show up in post-market reporting and in independent case series rather than in a 12-month trial. For Evolysse, that body of experience does not exist yet. That is a statement about how much is known, not a finding of a problem.
If you are choosing between them for a nasolabial fold, the honest position is that both are approved for it, neither has been tested against the other, and the difference in published follow-up is 12 months against 18 for Vollure XC and 24 weeks for Ultra XC.
Go to an emergency department or call 911 if any of these happen during or after a filler injection:
Sudden change or loss of vision in one or both eyes
Pain that is far worse than the procedure should reasonably cause
Skin that goes white or pale in a patch, then turns dusky, grey or mottled
Weakness on one side, a drooping face, slurred speech or confusion
These are the signs of filler entering a blood vessel. Published guidance treats a suspected eye event as a same-hour emergency and a suspected skin event as a same-day one. One caution about pain: in a survey of 52 experienced injectors, pain was mild or absent in 47% of the intravascular events they reported. Pain is not a reliable alarm, and its absence is not reassurance.
Swelling is still growing after the first few days instead of settling
A lump has not softened
Redness is spreading outward from an injection site
Tenderness, swelling or a new lump appears weeks or months later, which can mean a delayed inflammatory reaction or an infection
The filler looks like it has shifted out of place
None of these are emergencies, but none of them should be left alone either.